News & Updates
Filter by Specialty:
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
byAudrey Abella
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
byAudrey Abella
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
